Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial

OBJECTIVES: To determine whether low-dose spironolactone can safely lower arterial stiffness in patients with chronic kidney disease stage 3 in the primary care setting. DESIGN: A multicentre, prospective, randomised, placebo-controlled, double-blinded study. SETTING: 11 primary care centres in Sout...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Khai P, Jain, Poorva, Gill, Paramjit S, Heer, Gurdip, Townend, Jonathan N, Freemantle, Nick, Greenfield, Sheila, McManus, Richard J, Ferro, Charles J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769397/
https://www.ncbi.nlm.nih.gov/pubmed/26916697
http://dx.doi.org/10.1136/bmjopen-2015-010519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769397/
https://www.ncbi.nlm.nih.gov/pubmed/26916697
http://dx.doi.org/10.1136/bmjopen-2015-010519

Ejemplares similares